Raoul J-L, Edeline J, Pracht M, Boucher E, Rolland Y, Garin E
Département d'oncologie médicale, centre Eugène-Marquis, rue de la bataille Flandres-Dunkerque, Rennes cedex, France.
Cancer Radiother. 2011 Feb;15(1):64-8. doi: 10.1016/j.canrad.2010.12.001. Epub 2011 Jan 13.
Hepatocellular carcinoma is now a major public health concern. In intermediate stages (one third of hepatocellular carcinoma patients), chemoembolization is the standard of care despite a poor tolerance and a moderate efficacy. Moreover, despite recent improvements, this technique seems in a dead end. Radioembolization could be an excellent tool for such patients. Currently (131)I-Lipiodol, (188)Re-Lipiodol, (90)Y-glass or resin microspheres are available. More recent and promising data come from microspheres, but phase II and III studies are needed before drawing any conclusion. In the future, the combination of radioembolization with systemic chemotherapy or targeted agents (particularly antiangiogenic drugs) seems very promising.
肝细胞癌目前是一个主要的公共卫生问题。在中期阶段（三分之一的肝细胞癌患者），尽管耐受性差且疗效一般，但化疗栓塞仍是标准治疗方法。此外，尽管最近有所改进，但这项技术似乎已陷入困境。放射性栓塞可能是这类患者的理想工具。目前有（131）I-碘油、（188）铼-碘油、（90）钇玻璃或树脂微球。最新且有前景的数据来自微球，但在得出任何结论之前还需要进行II期和III期研究。未来，放射性栓塞与全身化疗或靶向药物（特别是抗血管生成药物）联合使用似乎非常有前景。
